Celcuity, Inc. (CELC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$95.70-0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Improve earnings to positive by FY 2027: EPS -1.1% vs 0.7% target.
Celcuity plans to launch gedatolisib in Q3 2026. The FDA decision is key. The company raised $500 million to fund operations through 2027. They also announced a share buyback program.
The recent $500 million debt may dilute shares and hurt value. The stock dropped 20% from its high. Litigation and negative news challenge the launch. Losses continue with negative EPS expected this year.
The price is about 28% below our fair value of $160. The market expects a tough near-term with losses and risks. Our view sees potential if the launch succeeds and financing holds.
Breaks if: EPS remains negative through FY 2027
Breaks if: Cash and debt run out before end of 2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making with volatile management, which adds uncertainty to its future performance.
The market appears to have low expectations for CELC, given its recent earnings miss and overall weak financial performance compared to peers. There is a low level of fragility in the current market setup, indicating that significant negative surprises may not be fully priced in.
Management is on track with key priorities, including the commercial launch of gedatolisib and financing operations through 2027. However, the recent earnings miss and weak performance raise concerns about the company's ability to meet future expectations.
The long-term thesis hinges on the successful launch of gedatolisib and the performance of sector bellwethers. Additionally, macroeconomic factors, such as the jobs report and recession fears, could significantly impact CELC's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company beat earnings expectations in Q2 2026. Management confirmed it will begin shipping REVTORPYK in late Q3 2026. This news raises expectations for future revenue generation. There are no new threats to the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain sufficient liquidity to fund operations through 2027 using cash, cash equivalents, investments, and debt facilities.
Stated in 2 of last 2 quarters. Cash, cash equivalents and short-term investments increased from $387.1M at 2026-Q1 to $754.0M at 2026-Q2, boosted by $557.2M net proceeds from convertible notes offering. Management expects these resources plus debt drawdowns to fund operations through 2027, indicating delivery on liquidity management.
“We expect cash, cash equivalents, investments and drawdowns on our debt facility to finance our operations through 2027.”
“We expect cash, cash equivalents, investments and drawdowns on our debt facility to finance our operations through 2027.”
Breaks if: Launch delayed beyond Q3 2026
Complete commercial launch of REVTORPYK (gedatolisib) following FDA approval, with shipments expected late Q3 2026.
Stated as a priority in 2 of last 2 quarters. Management confirmed FDA approval in July 2026 and commercial launch activities commenced immediately, with shipments expected late Q3 2026. This trajectory matches management's stated timeline and shows delivery on the launch commitment.
“We are on track to begin shipping REVTORPYK late in the third quarter of 2026.”
“We are on track to launch gedatolisib commercially in anticipation of its potential FDA approval in the third quarter of 2026.”
Breaks if: Buyback program canceled or not executed
In the next 1 to 3 years, CELC's outlook remains uncertain, influenced by both internal execution and external market conditions. Not investment advice.